Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: BrazíliaFázis nélkül

Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality

A legfontosabb adatok

Ki végzi
epHealth
Hol
Afogados da Ingazeira és Florianópolis (Brazília)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Résztvevők
45 000 fő, tervezett
Kezdés
2026. nov.
Várható befejezés
2027. nov.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • ARISE Strategy
A regiszteradat frissítve
2026. október 30.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akik az alapellátásban regisztráltak Afogados da Ingazeirában, és náluk esedékes a 2-es típusú cukorbetegség szűrése. Bevonnak olyan egészségügyi dolgozókat is, akik a szűrési stratégiában dolgoznak és részt vesznek a képzésén.

Életkor
18 éves vagy idősebb felnőttek. Szűrési csoport: 35 év felettiek, vagy 18–34 évesek túlsúllyal vagy elhízással és legalább egy kockázati tényezővel.
Nem
Minden nem részt vehet.
A betegség stádiuma
Olyan emberek, akiknél még nem ismert cukorbetegség, és esedékes a prediabétesz vagy a 2-es típusú cukorbetegség szűrése.

A részvétel fő kizáró okai

  • Akiknél korábban már bizonyítottan volt cukorbetegség
  • Akiket nemrég már szűrtek
  • Az a szakember, aki lemarad a képzésekről

A regiszter feltételei, szó szerint

Mind a 4 feltétel megnézéseKevesebb

Ki vehet részt

  • POPULATION FOR CARE-RELATED DATA: The population will consist of adults registered with municipal Primary Health Care who meet the eligibility criteria for T2DM screening on the index date of each period. In general, the following will be considered potentially eligible: (i) individuals aged 35 years or older; (ii) individuals aged 18 to 34 years with overweight or obesity and at least one risk factor defined in the protocol; (iii) individuals aged 18 years or older presenting certain high-risk conditions. Factors and conditions assessed include cardiovascular disease, dyslipidemia, arterial hypertension, prior laboratory-confirmed prediabetes, prior gestational diabetes, current pregnancy, antipsychotic use, obstructive sleep apnea syndrome, HIV/AIDS, cystic fibrosis, and history of transplantation
  • HEALTHCARE PROFESSIONAL PARTICIPANTS: Professionals will be considered research participants exclusively for the components evaluating educational impact, acceptability, and usability of the strategy. Eligible professionals will be those aged 18 years or older, currently working in the municipality, directly involved in the implementation or operationalization of the strategy, who attend the training corresponding to their role and agree by signing the Informed Consent Form (ICF). Participation in institutional training will not be contingent on participation in the research. Refusal to authorize the use of questionnaire data will not result in any functional, hierarchical, or institutional penalty

Ki nem vehet részt

  • POPULATION FOR CARE-RELATED DATA: Individuals with prior evidence of diabetes or with recent screening will be excluded, according to the windows and rules defined in the protocol. Criteria were limited to information that could be reliably identified in the structured fields of available data sources. The absence of a record of a given condition will not be interpreted as confirmation of its absence
  • HEALTHCARE PROFESSIONAL PARTICIPANTS: Professionals absent from training sessions due to vacation, leave, medical leave, or any other reason will not be included in the research components related to healthcare professionals

Helyszínek itt: Brazília

  • Municipal Health Secretariat of Afogados da IngazeiraAfogados da Ingazeira, BrazíliaContact: Pedro M PereiraNo longer taking part
  • epHealthFlorianópolis, BrazíliaContact: Pedro M PereiraNo longer taking part

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for T2DM), among adults eligible for screening registered at UBS (Primary Health Care Units) in Afogados da Ingazeira, during the 12 months post-implementation, compared to a reference value estimated from a historical 12-month period in the same municipality.

A teljes eredeti leírásKevesebb

Methodology: Pragmatic, quasi-experimental, single-arm effectiveness and implementation study with a historical comparator. In each period, the analytic population will be defined by eligibility on the respective index date. In the historical period, data will estimate the reference proportion of the primary outcome and historical values of applicable secondary outcomes. In the post-intervention period, individuals eligible on the index date will be followed for 12 months via care records. Individuals who become eligible after the post-intervention index date may receive care actions under the strategy and be included in operational, implementation, and exploratory analyses, but not in outcome denominators fixed at the index date.

The study will take place in Afogados da Ingazeira, Pernambuco, covering all 15 UBS with an affiliated Family Health Team. Research-specific technological components will incur no additional cost to the municipality.

ARISE comprises two components:

1. Digital analytics layer, built on the existing epHealth infrastructure. It uses structured data from e-SUS PEC to apply predefined T2DM screening eligibility rules. Identified individuals appear in operational lists and may generate alerts for UBS managers and community health workers, supporting visits, scheduling, test requests, follow-up, and patient return. It may also flag: delays over 60 days between test request and completion, availability of lab results, and need for active case-finding. No test, diagnosis, prescription, referral, or treatment is automated; clinical decisions remain with APS professionals and managers. 2. Professional training. UBS managers, community health workers, physicians, nurses, and nursing technicians will be trained on the PCDT-DM2 and ARISE workflows, before the digital layer's activation. Professionals are research participants only for evaluating educational impact, acceptability, and usability, provided they attend the relevant training and sign the Informed Consent Form (ICF). Training participation is independent of research participation; declining data use carries no functional or institutional penalty.

A census-based approach will define population size. The primary analysis includes all individuals eligible on the post-intervention index date; final numbers depend on municipal database findings. Power calculations covered 8,000-30,000 eligible individuals and historical T2DM diagnosis proportions of 0.80%-0.90%. A population of ~14,000-15,000 eligible individuals yields ~80% power to detect a ~25% relative increase, for historical proportions of 0.85%-0.90%. For professional-related components, a census approach covers all eligible categories per the updated roster of active professionals directly involved.

Statistical analysis: The post-intervention proportion of confirmed T2DM diagnosis will be compared to the historical reference using a two-tailed one-proportion test (5% significance level). Point estimates, 95% CIs, absolute differences, and proportion ratios (where applicable) will be reported. Adjusted analyses may use logistic regression. Change in professionals' knowledge will be analyzed via paired intra-individual pre/post-training score differences. RE-AIM indicators will be mainly descriptive. Acceptability, training reaction, and workflow perception blocks will be scored separately (1-5). Usability will be assessed via the System Usability Scale (0-100) among professionals who directly used the digital component.

The study was approved by the Research Ethics Committee (REC), CAAE n. 00260026.5.0000.5330, approval opinion n. 8.705.723.

Primary outcome: Confirmed T2DM diagnosis during the observation period, treated as a binary individual indicator.

A vizsgálat csoportja

  • ARISE StrategyA vizsgált kezelés

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Single-arm Intervention Study With Historical Comparator to Evaluate the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. október 30.